Cullen/Frost Bankers, Inc. Spero Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 2,000 shares of SPRO stock, worth $2,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$2,360
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SPRO
# of Institutions
49Shares Held
13.9MCall Options Held
200Put Options Held
200-
Anson Funds Management LP Dallas, TX3.75MShares$4.43 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$2.08 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.6 Million14.54% of portfolio
-
Acadian Asset Management LLC Boston, MA1.07MShares$1.26 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny975KShares$1.15 Million0.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $41.4M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...